Company
Investment-firm
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
O2h Ventures
O2h Ventures is a UK-based investment firm that focuses on backing biotech through tax-efficient EIS and SEIS investments.
Sector
Subsector
Keywords
count Of Investments
Apple Tree Partners
Apple Tree Partners is a life sciences venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Pacific Horizon Ventures
Pacific Horizon Ventures is a Seattle-based venture capital firm focused on early-stage life science and healthcare technologies.
Sector
Subsector
Location
count Of Investments
count Of Exists
Quaker BioVentures
Quaker BioVentures is a venture capital firm investing in life science companies.
Sector
Subsector
Location
count Of Investments
count Of Exists
Financials
Investments6
Auxesia Orion
Auxesia Orion, Inc. is a company focused on developing tech-enabled patient-centric therapeutics for orphan diseases.
Sector
Subsector
Location
total rounds
Helios Orion
Helios Orion is a corporate strategy advisory firm that partners with healthcare companies to assist in their growth.
Sector
Subsector
Keywords
Location
total rounds
Renexxion
Renexxion Ireland Innovation develops naronapride drugs to treat gastrointestinal disorders.
Sector
Subsector
Keywords
Location
total rounds
Co-Investors
Exits1
Altheos
Altheos, Inc. is a biopharmaceutical company developing novel small molecule drugs.
Sector
Subsector
Keywords
Location
total rounds
total raised
People
Founders1
Ken Kengatharan
Dr. Kengatharan is a co-founder of several San Francisco bay-area based biopharmaceutical companies where he held responsibilities in R&D and corporate development. He is currently President and CEO of Auxesia Orion, Executive Chairman of Helios Orion, and a member of the board of Renexxion. He is also a managing partner at Atheneos Ventures, a San Francisco bay area based evergreen healthcare incubator fund focusing on opportunities in orphan drugs and rare diseases. Previously he was President and CEO of Armetheon (renamed Espero Biopharma following a merger) and prior to that President and CSO of Athos. He is the former Vice President of, Pre-Clinical R&D of Athenagen (re-named CoMentis following a merger). During the last 20 years, Dr. Kengatharan has been critical to the development of multiple drug candidates from concept to clinical development. Since setting up his first company in the late 1990s, with a great team and highly supportive investors in each case, he has been critical to setting-up multiple companies and raising >$160MM in private equity, and closing partnership transactions in excess of $1bn in deal value. He has served on the boards of EPi3 (UK), Athenagen, Athos, Armetheon, he has been an advisor/advisory board member at Spire-BioVentures, Cardinal Free Clinics (Stanford University School of Medicine), a mentor at the University of California, San Francisco (UCSF)’s entrepreneurship program and a panel judge for the Stanford Business School’s Ignite Program. He trained as a cardiovascular pharmacologist in London and at Stanford after obtaining his Ph.D. in pharmacology from the University of London under the supervision of eminent British pharmacologist and Nobel laureate, Prof. Sir John Vane FRS and Professor Christoph Thiemermann. Dr. Kengatharan obtained his MBA (with Distinction) from Durham University in England, where he focused on Biotech Finance and Entrepreneurship. His current interests, based on previous experience, include capital-efficient R&D, application of distributed ledger technology, AI, and novel paths to raising private equity, in healthcare.
current job
organization founded